{
    "symbol": "SUPN",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-07 08:10:35",
    "content": " For the first half of this year, total revenues were $322.6 million, representing an 18% increase over the same period last year. And adjusted non-GAAP operating earnings were $65.7 million, a 5% increase over the first half of last year, reflecting continued significant investment in Qelbree and its launch activities. Regarding GOCOVRI, the product delivered another quarter of solid growth with net sales reaching $24.7 million in the second quarter of 2022, representing a 23% increase compared to the $20.1 million reported by Adamas in the second quarter in 2021. Oxtellar XR continues to perform well, delivering a strong quarter with net product sales of $30 million, a 20% increase compared to the same period last year, while net product sales of Trokendi XR were approximately $72 million, down from $79 million last year. Total revenue for the second quarter 2022 was $170.1 million, a 20% increase compared to $141.3 million in the same quarter last year. For the second quarter of 2022, combined R&D and SG&A expenses were $116.9 million as compared to $85 million for the same period in 2021. On a non-GAAP basis which excludes amortization of intangibles, share-based compensation, contingent consideration and depreciation, adjusted operating earnings were $37.6 million compared to $37.4 million in the second quarter of 2021. Total revenue for the 6 months ended June 30, 2022, was $322.6 million, an 18% increase compared to $272.3 million in the same period last year. For the 6 months ended June 30, 2022, combined R&D and SG&A expenses were $228.2 million as compared to $180.7 million for the same period in 2021. Amortization of intangible assets for the first 6 months of June 30, 2022, was $41.3 million compared to $12 million for the same period in 2021. Operating earnings on a GAAP basis for the first 6 months ended June 30, 2022, was $13.3 million as compared to $47.3 million for the same period in 2021. Other income expense for the first 6 months ended June 30, 2022, was $12.7 million of income as compared to $5.2 million of expense in the first 6 months of 2021. Income tax for the first 6 months ended December 30, 2022, was a tax benefit of $7.4 million as compared to income tax expense of $12.7 million for the same period in 2021. On a net -- on a non-GAAP basis which excludes amortization of intangibles, share-based compensation, contingent consideration and depreciation, adjusted operating were $65.7 million compared to $62.7 million in the same period of 2021. GAAP net earnings was $33.5 million for the first 6 months ended June 30, 2022, or $0.57 per diluted share compared to $29.4 million or $0.54 per diluted share in the same period last year. Overall, we expect full year 2022 GAAP operating earnings to range from $20 million to $40 million and non-GAAP operating earnings to range from $130 million to $165 million."
}